
"INTEGRATING CYTOPROTECTION AND REPERFUSION"
New Perspectives on Expanding and Combining Research and Development of Acute Stroke Treatment Drugs and Devices
DAY 1 THURSDAY MORNING, MARCH 27
* All Meals are served in Salons 1-3 Adjacent to the Ballroom
* Ballroom – Location of all General Sessions – Main Floor of Hotel
* Presentations are 10 minutes each.
7:00 – 8:00 Full Breakfast Provided -- Salons 1-3
8:00 – 8:40 WELCOME AND OPENING REMARKS -- Ballroom
SETTING THE STAGE
Welcome to STAIR XIII - Co-chairs Greg Albers and Marc Fisher
"A Future Vision of Acute Stroke Research and Treatment" - Jeff Saver
8:40 – 10:25 SESSION 1 WHAT HAVE WE LEARNED FROM RECENT ACTUE STROKE TRIALS?
Session Chairs: Jim Grotta and Opeolu Adeoye
-
Lessons learned from ESCAPE, NEXT and FRONTIER; Next steps for Cytoprotection – Michael Hill
-
Implications of TIMELESS, TRACE III, ARAMIS and TEMPO 2 – Carol Xiong
-
Large EVT core studies: Is there an outer limit? – Jeremy Heit
-
Large core medical therapy, insights from CHARM – Kevin Sheth
ROUNDTABLE PANEL DISCUSSION: Yilong Wang, Steve Warach, plus others TBD
10:40 – 10:55 Refreshment Break -- Foyer Outside of Ballroom
10:55 – 12:25 SESSION 2 CYTOPROTECTION - RENEWED PROMISE AND NEW APPROACHES
Session Chairs: Eva Mistry and Mike Tymianski
-
What are the most promising cytoprotectant agents and neuronal/glial pathways? - Marion Buckwalter
-
Can we define different types of cerebroprotection depending on the time of intervention – Pat Lyden
-
Should we target no reflow/residual perfusion lessions following EVT?– Thanh Nguyen
-
How can we evaluate cytoprotective effects in phase II trials as did Revalesio and ApT – Marc Ribo
ROUNDTABLE PANEL DISCUSSION: Marcelo Rocha, Liz Dallimore, Renyu Liu, plus others TBD
12:25 – 1:20 LUNCH PROVIDED -- Salons 1-3
DAY 1 THURSDAY AFTERNOON -- Ballroom
1:25 – 2:45 SESSION 3 INTEGRATING CYTOPROTECTION AND REPERFUSION: TRIALS AND PLATFORMS
Session Chairs: Andrei Alexandrov and Hooman Kamel
-
Key Considerations for Integrating Drug and Device Trials – Larry Wechsler
-
Ongoing Cytoprotective Trials: Study Designs highlighting major trials – David Liebeskind
-
EVT Trials; Recent (ESCAPE, MeVo, DISTAL) and low NIHSS subjects – Urs Fischer
-
STEP / ACT-GLOBAL – Pooja Khatri
ROUNDTABLE PANEL DISCUSSION: A.J. Wakhloo, Jordon Elm, plus others TBD
2:45 – 3:45 SESSION 4 EXPEDITING URGENT EVALUATION & TREATMENT OF ACUTE STROKE
Session Chairs: Edward Jauch and Raul Nogueira
-
AI Impact on acute stroke transfer, treatment and trials – Greg Albers
-
Surging DOAC usage and Implications for Acute Stroke Research – Jennifer Frontera
-
Detecting ICH and LVO in the ambulance – Wade Smith
-
Prehospital Therapy: FRONTIER, iNTERACT4, MSU – Johanna Ospel
ROUNDTABLE PANEL DISCUSSION: Shadi Yaghi, Lucy He, plus others TBD
3:45 – 4:00 Refreshment Break -- Foyer Outside of Ballroom
4:00 – 5:00 SESSION 5 REGULATORY PERSPECTIVES ON KEY CLINICAL TRIAL ISSUES
Session Chairs: Greg Albers and Marc Fisher
-
New Approaches at the FDA – FDA Representatives
-
FDA Panel (CDER & CDRH) Answers to Stroke Community Questions pre-submitted and audience engagement
ROUNDTABLE PANEL DISCUSSION: FDA: Heather Fitter, Shawna Cutting (CDER), Xiaolin Zheng (CDRH)
6:30 – 7:30 SPONSORED RECEPTION -- Studio B – Main Floor of Hotel
7:30 – 9:00 DINNER BANQUET -- Salons 1-3
FOLLOWED BY SPECIAL PRESENTATION
Walter Koroshetz, NINDS Director
Dr. Koroshetz will be interviewed by Lee Schwam with Audience Participation
DAY 2 FRIDAY MORNING, MARCH 28
7:00 – 8:00 FULL BREAKFAST PROVIDED -- Salons 1-3
8:00 – 10:30 WORKSHOPS TO DEVELOP RECOMMENDATIONS
* All Participants - Please Report Directly to Your Assigned Workshop at 8:00 AM
* All Workshops held in Studios B, D and F on Main Floor of Hotel
* Participants divide into three groups according to their topic choice
* Each group will develop recommendations on their selected topic
WORKSHOP 1: OPTIMIZING REPERFUSION TRIALS
Studio - D Facilitators – Chair: Bruce Campbell, Co-chair: David Fiorella, Recorder: TBD
WORKSHOP 2: PRIORITIES FOR CYTOPROTECTION TRIALS
Studio - B Facilitators – Chair: Sean Savitz, Co-chair: Edgar Samaniego , Recorder: Johannes Boltz
WORKSHOP 3: NEW TRIAL DESIGNS AND STRATEGIES INCLUDING AI AND PLATFORMS
Studio - F Facilitators – Chair: Joe Broderick, Co-chair: Scott Kasner, Recorders: Yasmin Aziz & Paul Wechsler
10:30 – 10:45 Refreshment Break
10:45 – 12:00 WORKSHOP CHAIRS PRESENT RECOMMENDATIONS TO FULL ASSEMBLY
Ballroom Drafting of consensus statements is initiated – Chaired by Greg Albers and Marc Fisher
12:00 – 12:15 CLOSING COMMENTS AND ADJOURNMENT
STAIR MISSION STATEMENT
The STAIR Consensus Conferences, via a collaboration of medical academia, the healthcare industry and government agencies, are intended to advance and accelerate stroke research to ultimately result in improved stroke acute treatment, care and prevention. To achieve this goal, STAIR will:
-
Develop new approaches to overcome barriers impeding stroke drug and device development
-
Identify, clarify and communicate the implications of new research to the stroke field
-
Publish STAIR Workshop recommendations developed by participants which address these concerns
-
Promote adoption of STAIR solutions by research, industry, clinical and government communities